HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Future expectations in the prophylaxis of intestinal bleeding.

Abstract
Prophylaxis of gastrointestinal bleeding is attempted in widely varying situations. In NSAID-induced peptic ulcer, the advantage of selective cyclooxygenase 2 inhibitors with regard to gastrointestinal damage has yet to be translated into an advantage in overall morbidity. Strategies for primary and secondary prevention of variceal bleeding have been established. Therapy tailored to hepatic venous pressure gradient has the potential to achieve clinical relevance. Several methods have been developed to prevent postpolypectomy bleeding, but their optimal risk-tailored application has yet to be demonstrated. Although octreotide treatment seems to be beneficial in reducing the blood loss from angiodysplasias, controlled studies to determine its optimal use are awaited. Stress-ulcer prophylaxis is commonly applied in critically ill patients. Although data indicate that H2-receptor antagonists and omeprazole are effective in preventing clinically significant bleeding, evidence for an advantage with respect to length of hospital or intensive-care-unit stay, as well as mortality, is still lacking. Since there is misuse of acid-suppressing drugs on regular wards, in-house guidelines may offer the potential for saving costs and reducing inappropriate prescription.
AuthorsF H Klebl, J Schölmerich
JournalBest practice & research. Clinical gastroenterology (Best Pract Res Clin Gastroenterol) Vol. 22 Issue 2 Pg. 373-87 ( 2008) ISSN: 1521-6918 [Print] Netherlands
PMID18346690 (Publication Type: Journal Article, Review)
Chemical References
  • Adrenergic beta-Antagonists
  • Anti-Inflammatory Agents, Non-Steroidal
  • Anti-Ulcer Agents
  • Vasoconstrictor Agents
Topics
  • Adrenergic beta-Antagonists (therapeutic use)
  • Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
  • Anti-Ulcer Agents (therapeutic use)
  • Critical Illness
  • Forecasting
  • Gastrointestinal Hemorrhage (etiology, prevention & control)
  • Hemostasis, Endoscopic
  • Humans
  • Primary Prevention
  • Risk Factors
  • Vasoconstrictor Agents (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: